3 Best Performing ASX shares in week 49, 13 December 2021
Marc Kennis, December 20, 2021
3 Best performing ASX shares: Resources stocks dominate last week’s Top 3 Best performing ASX shares with Uranium play Berkeley Energia (ASX:BKY) up 44.8% and iron ore explorer Magnetite Mines (ASX:MGT) up 27.3%. IVF specialist Virtus Health (ASX:VRT) rounds out the Top 3 with a 27.1% gain last week.
1. Berkeley Energia (ASX:BKY)
Industry: Energy
Berkeley Energia Limited (BKY, formerly Berkeley Energy Limited) is a uranium exploration and development company with a quality resource base in Spain. The company’s primary focus is on advancing its wholly owned flagship Salamanca project, which comprises the Retortillo, Zona 7, Alameda, Gambuta deposits and Salamanca mine.
Market Cap: $94M
12 month high / low: $0.79 – $0.14
2. Magnetite Mines (ASX:MGT)
Industry: Basic Materials
Magnetite Mines Limited (MGT) is an iron ore focussed mineral exploration company exploring for magnetite iron ore in the Mawson Iron Province of South Australia. The company’s flagship projects are the Razorback Iron and Mawson Iron Project.
Market Cap: $88M
12 month high / low: $0.094 – $0.011
3. Virtus Health (ASX:VRT)
Industry: Healthcare
Virtus Health Limited (ASX:VRT) is a healthcare services company that provides a variety of Assisted Reproductive Services, Specialised Diagnostics and Day Hospitals cross the eastern states of Australia. Virtus provide these services to its patients through a network of fertility clinics, embryology laboratories, andrology laboratories, medical diagnostic testing laboratories and day hospitals.
Market Cap: $582M
12 month high / low: $7.47 – $4.94
Learn more about ASX-listed stocks with
Stocks Down Under!
Subscribe to Stocks Down Under today!
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…